LM9

Overview

LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4 /MyD88/ NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Chronic Disease and Inflammation | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Atherosclerosis and Inflammation | Products > Disease Areas > Obesity | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Collagen | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > MyD88 | Products > Signaling Pathways > Toll-like Receptor (TLR)

Product Information

• Catalog No.: HY-180336
• CAS No.: 2249864-11-5
• Molecular Formula: C24H27N5O5S
• Molecular Weight: 497.57
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source